Johnson & Johnson Innovation LLC https://www.jnjinnovation.com and Children’s National Health System (Children’s National) https://childrensnational.org are launching JLABS @ Washington D.C https://www.jlabs.jnjinoation.com to be located at the new Children’s National Research and Innovation Campus in Washington D.C.
The JLABS @ Washington, D.C site will be open to pharmaceutical, medical device, consumer and health technology companies to help advance the development of new drugs, medical devices, precision diagnostics and health technologies, which will help doctors in pediatrics.
Kurt Newman, MD., President and CEO at Children’s National said, “We believe the JLABS model is exactly what is needed to help drive discoveries that are then rapidly translated into new treatments and technologies.”
Children’s National leads the FDA-funded National Capital Consortium for Pediatric Device innovation in collaboration with the University of Maryland. The Consortium has provided mentorship support to more than 60 medical device startups to help advance their pediatric innovations.
Five of the devices assisted by the program have received either CE Mark approval or FDA market clearance. Children’s National has also spun out more than 20 start-up companies from its own intellectual property.
The new campus will enable Children’s National to expand their research programs to meet high impact opportunities in pediatric genomic and precision medicine anchored by the organization’s “Center for Genetic Medicine Research and Rare Disease.” Institute.
According to Melinda Richter, Global Head of Johnson & Johnson Innovation, “JLABS aims to remove the barriers for start-ups by providing resources needed without taking any equity or intellectual property and encourages collaboration by providing access to leading experts, executives and funders to grow their companies.”
The Biomedical Advanced Research and Development Authority BARDA within the office of the Assistant Secretary for Preparedness and Response https://www.medicalcountermeasures.gov at HHS is going to collaborate with Johnson & Johnson to develop an innovation zone dedicated to advancing medical countermeasures.
This will include developing ways to secure the U.S from chemical, biological, radiological, and nuclear threats as well as from pandemic influenza and emerging infectious diseases. Collaboration between Janssen Research & Development LLC and BARDA will accelerate new therapies and vaccines plus promote and support the development of related treatments and prevention solutions.
In addition, the “JLABS @ Washington D.C. Children’s QuickFire Challenge aims to accelerate the development and commercialization of pediatric centered healthcare innovation. Innovators with the best ideas, technologies, or solutions impacting pediatric oncology, pediatric surgical care, and influenza.
The winners of the Challenge will receive up to $150,000 in grant funding, and residency at JLABS @ Washington D.C for one year and receive mentoring across the Johnson & Johnson Family of companies. For more information about the application process, go to https://jlabs.tv/DC.